The Centre for Process Innovation (CPI) has officially launched the new £38m National Biologics Manufacturing Centre in Darlington, Co. Durham.
The Centre aims to significantly increase the UK’s manufacturing capability in biologics and strengthen the UK’s position as the location of choice for life science companies. It will support companies of all sizes to develop, prove, demonstrate, scale up and commercialise new biologic process technologies.
Biopharmaceuticals are medicines produced through biotechnology which represent the cutting-edge of biomedical research.
They are delivering significant advances in healthcare with completely new medicines being developed for serious illnesses, including cancer; blood conditions; auto-immune disorders such as rheumatoid arthritis, and neurological disorders like multiple sclerosis.
The use of biotechnology can also facilitate the development of the next generation of personalised medicines for specific diseases and patient groups.
You can read the full release here.